CPHI & PMEC China 2024 returns to Shanghai with unprecedented global participation amid soaring pharma demand China's premier pharmaceutical event sees record-breaking attendance, fueled by post-pandemic demand surge and regional market expansion. Featuring 3500 exhibitors and 60,000 attendees, the event showcases the dynamic growth and innovation across Asia's pharmaceutical supply chain. CPHI & PMEC China (June 19-21st) returns to the Shanghai New International Expo Center amid soaring demand across the pharmaceutical supply chain in Asia. China, already the primary source of pharmaceutical ingredients and starting materials globally, has also seen domestic demand improve rapidly post-pandemic. Consequentially, exhibitors are reporting robust growth across most Asian countries, with expected attendance significantly up year-on-year.
READ MORE
Montelukast will carry ‘more prominent warnings’ of neuropsychiatric reactions The Medicines and Healthcare products Regulatory Agency also advised prescribers to be alert for neuropsychiatric reactions, including sleep disorders, hallucinations, anxiety and depression, and changes in behaviour and mood. Further safety measures will be introduced for montelukast, a drug used for the treatment of asthma, to ensure patients are informed of the risk of neuropsychiatric reactions, following a safety review.
READ MORE
Optimized amide bond reaction using heterocyclic compounds and carboxylic acid TOHOKU UNIVERSITY DMAPO and Boc2O chemicals and a single reaction vessel IMAGE: OPTIMIZED REACTION CONDITIONS FOR AMIDE BOND FORMATION IN NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS USING CARBOXYLIC ACID REQUIRES ONLY 4-(N,N-DIMETHYLAMINO)PYRIDINE N-OXIDE (DMAPO) AND DI-TERTBUTYL DICARBONATE (BOC2O) IN A SINGLE REACTION VESSEL. A high-yield, one-pot, scalable reaction facilitates the production of biologically relevant amide compounds using less reactive nitrogen-containing heterocyclic compounds and carboxylic acid without the use of heat or special equipment.
READ MORE
